CAPR - Capricor Therapeutics GAAP EPS of -$0.25 beats by $0.05 revenue of $6.19M beats by $3.02M
2023-11-14 16:08:08 ET
More on Capricor Therapeutics
- Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular Dystrophy
- Capricor Therapeutics Q3 2023 Earnings Preview
- Capricor Therapeutics Q3 2023 Earnings Preview
- Seeking Alpha’s Quant Rating on Capricor Therapeutics
- Historical earnings data for Capricor Therapeutics
For further details see:
Capricor Therapeutics GAAP EPS of -$0.25 beats by $0.05, revenue of $6.19M beats by $3.02M